Standard BioTools

Standard BioTools EBIT Growth

The Year-over-Year EBIT Growth of Standard BioTools (LAB) as of Oct 8, 2026 is 46.75 %. In the previous year, Year-over-Year EBIT Growth was -128.77 % — a change of -136.31% (higher).

EBIT Growth

46.75 %

YoY

-136.31%

Last updated:

Year-over-Year EBIT Growth of Standard BioTools is 2025 46.75 % . Year-over-Year EBIT Growth of Standard BioTools was 2024 -128.77 % . It decreases by -136.31% higher compared to the previous year.

The Standard BioTools EBIT Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Growth
Date
EBIT Growth
Jan 1, 2018
18.56 USD
Jan 1, 2019
-31.35 USD
Jan 1, 2020
19.06 USD
Jan 1, 2021
-33.51 USD
Jan 1, 2022
-179.57 USD
Jan 1, 2023
59.38 USD
Jan 1, 2024
-128.77 USD
Jan 1, 2025
46.75 USD
The Standard BioTools EBIT Growth history
YEAREBIT GrowthYoY
46.75 %-136.31%
-128.77 %-316.84%
59.38 %-133.07%
-179.57 %+435.95%
-33.51 %-275.81%
19.06 %-160.79%
-31.35 %-268.88%
18.56 %-8.39%
20.26 %-144.12%
-45.93 %-1,516.24%
3.24 %—
Access this data via the Eulerpool API
Get Free API Key

Standard BioTools Stock analysis

What does Standard BioTools do? Fluidigm Corp is a biotechnology company specializing in innovative devices and solutions for DNA sequencing. The company was founded in 1999 in San Francisco and is currently headquartered in South San Francisco. It developed the Microfluidic Technology-Sensor, which allows for handling tiny amounts of fluids in a small space. This technology has enabled researchers to analyze complex samples and collect data with high accuracy. The company operates in two main segments: Analytical Instruments and Sample Preparation. In the Analytical Instruments segment, Fluidigm offers various devices suitable for DNA sequencing, including the Juno, C1, and Biomark platforms. It also provides a wide range of consumables to facilitate sample preparation. The Sample Preparation segment offers products and services to prepare and process samples for analysis, including microfluidic technology chips and modules, single-cell sequencing systems, and products for next-generation sequencing. Fluidigm serves customers in various industries, such as genomics research, cancer research, and medical fields, with a strong presence in North America, Europe, and Asia. The company is known for its continuous investment in research and development, as well as its innovative technologies and patents. Overall, Fluidigm's Microfluidic technology platform allows researchers to collect data in a small space with high accuracy. With a diversified portfolio of products and services, the company is well-positioned to continue growing and expanding its market presence in the coming years. Standard BioTools is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Standard BioTools stock

Year-over-Year EBIT Growth of Standard BioTools is 46.75 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year EBIT Growth Standard BioTools since 2006 – with annual values, charts, and detailed analysis.

EBIT growth measures the percentage change in operating earnings. It shows whether a company's core operations are becoming more profitable.

To evaluate Year-over-Year EBIT Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBIT Growth.

Year-over-Year EBIT Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBIT Growth's Standard BioTools historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Growth — Standard BioTools

Revenue GrowthRevenue CAGR 3YRevenue CAGR 5YRevenue CAGR 10YEarnings GrowthEPS GrowthEBIT GrowthEBIT CAGR 3YEBIT CAGR 5YEBIT CAGR 10YDividend GrowthFCF GrowthBook Value GrowthEarnings CAGR 3YEarnings CAGR 5YEarnings CAGR 10YEPS CAGR 3YEPS CAGR 5YEBITDA Growth YoYEBITDA CAGR 3YEBITDA CAGR 5YGross Profit GrowthOCF Growth YoYEmployee GrowthDividend CAGR 3YDividend CAGR 5YDividend CAGR 10YAsset GrowthEquity GrowthDebt GrowthCapEx GrowthFCF CAGR 3YFCF CAGR 5YMarket Cap GrowthShare Count Growth

All Key Metrics — Standard BioTools